Moat Ross's Form 4 filing
Kiniksa Pharmaceuticals International, plc (KNSA) · filed Apr 23, 2025
- Accession no.
- 0001415889-25-011209
- Filed
- Apr 23, 2025
- Trade date
- Apr 21, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $370.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Moat RossCIK 0001857177 | Officer (CHIEF COMMERCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2025 | Class A Ordinary Share | SSaleDisposed | −18,259 | $20.29F2 | −$370,475.11 | 9,415 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.05 and 20.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Referenced by the price of 1 transaction in Table I.